Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Inhibrx Biosciences, Inc. is a clinical-stage biotechnology company focused on developing biologic therapeutics for oncology and rare diseases. The company operates within the biopharmaceutical and biotechnology industries, with an emphasis on engineered protein-based medicines designed to target well-defined disease pathways. Its business model centers on advancing internally developed drug candidates through clinical development and, where appropriate, pursuing strategic transactions or partnerships.
The company’s primary value driver is its oncology pipeline, most notably INBRX‑109, a tetravalent death receptor 5 (DR5) agonist being evaluated for the treatment of unresectable or metastatic conventional chondrosarcoma. Inhibrx Biosciences traces its origins to the broader Inhibrx platform founded in 2017, which focused on modular protein engineering. In 2023–2024, the company underwent a significant strategic reorganization, separating certain assets into a privately held entity while the publicly traded company retained INBRX‑109 and adopted the name Inhibrx Biosciences, Inc.
Business Operations
Inhibrx Biosciences operates as a single-segment clinical-stage biotechnology company, generating no commercial product revenue and relying primarily on capital markets and prior strategic transactions to fund operations. Its core activities include preclinical research, clinical trial execution, regulatory engagement, and manufacturing oversight through third-party contract development and manufacturing organizations.
Operations are primarily based in the United States, with research and development activities supported by external vendors and clinical trial sites. The company controls proprietary biologic engineering technologies related to multivalent protein therapeutics, though following the corporate reorganization, certain platform technologies and pipeline assets were transferred to affiliated entities. As of publicly available disclosures, the company does not report material revenue from collaborations and maintains a lean operational structure focused on advancing INBRX‑109.
Strategic Position & Investments
The company’s strategic direction is centered on maximizing the clinical and regulatory value of INBRX‑109 in oncology, particularly in indications with high unmet medical need and limited approved treatment options. Management has emphasized disciplined capital allocation, streamlined operations, and a narrowed pipeline focus following the separation of non-core assets.
Historically, Inhibrx has executed significant transactions, including the transfer and monetization of certain biologic assets and the creation of affiliated entities to advance non-oncology programs. These actions were intended to unlock shareholder value and reduce development risk. Data inconclusive based on available public sources regarding any new material acquisitions or equity investments following the reorganization.
Geographic Footprint
Inhibrx Biosciences is headquartered in the United States, with its principal offices in California. The company’s operational footprint is primarily domestic, though its clinical development programs involve international trial sites, reflecting the global nature of rare cancer research and patient recruitment.
While the company does not maintain large-scale international offices, it has an indirect global presence through clinical research activities and relationships with international regulatory authorities. Its market influence is concentrated in North America, with selective engagement in Europe and other regions through multicenter clinical trials.
Leadership & Governance
Inhibrx Biosciences is led by an executive team with experience in biologics development, corporate strategy, and capital markets. The leadership emphasizes a focused development strategy, capital efficiency, and advancing differentiated assets through late-stage clinical milestones.
Key executives include:
- Mark Lappe – Chief Executive Officer
- Paul Foster – President and Chief Scientific Officer
- Harris Kupperman – Chief Financial Officer
The company is governed by a board of directors with backgrounds in biotechnology, finance, and corporate governance. Data inconclusive based on available public sources regarding recent changes to board composition or executive leadership beyond those listed.